Skip to Content

Galderma Group AG Registered Shares

GALD: XSWX (CHE)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
CHF 33.00TcwfxbcXspmxpx

Galderma's Diversified Dermatology Portfolio and Drug Pipeline Support Positive Outlook

Business Strategy and Outlook

Galderma is a pure-play dermatology company, with a leadership position in the self-care segment of the market, with more than 90% of total sales paid by consumers out of pocket. Its long-term revenue growth is supported by changing consumer behavior and perception around skin health and appearance. The company deploys an omnichannel go-to-market strategy, supported by a specialized, high-touch salesforce of over 1,900 employees reaching more than 110,000 healthcare professionals. This is complemented by a leading presence at dermatology congresses and an emphasis on educational, training, and loyalty programs to reinforce physician entrenchment.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of GALD so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center